

# Therapeutics in neuropathic pain - An overview

M. Subha, M. Arvind

Department of Oral Medicine and Radiology, Saveetha Dental College and Hospital, Saveetha University, Chennai, Tamil Nadu, India

**Correspondence:** M. Subha, Department of Oral Medicine and Radiology, Saveetha Dental College, Saveetha University, Chennai, Tamil Nadu, India.  
Phone: +91-9884141299. E-mail: doctorsubha@gmail.com

## ABSTRACT

Various definitions have been provided with regard to pain. In articular, neuropathic pain is a highly unpleasant sensation, which contributes to poor quality of life which is similar to patients with serious mental illness or severe heart diseases. Correct diagnosis of neuropathic pain is always challenging. It is essential to recognize neuropathic pain, identify the underlying cause, assess the impact of pain on the quality of life of the patient, and initiate appropriate treatment. This article limits itself to discuss about the neuropathic pain pertaining to orofacial structures. It includes trigeminal neuralgia, post-herpetic neuralgia, cancer neuropathic pain, and HIV neuropathy.

**Keywords:** Neuropathic pain, carbamazepine, trigeminal neuralgia, gabapentin, pregabalin

## Introduction

The International Association for the study of pain (IASP) defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. IASP in November 2010 further extended to define neuropathic pain as “Pain initiated or caused by primary lesion or dysfunction of the peripheral or central nervous system.<sup>[1]</sup>”. Neuropathic pain is a highly unpleasant sensation, which contributes to poor quality of life which is similar to patients with serious mental illness or severe heart dis-eases.<sup>[2,3]</sup> Correct diagnosis of neuropathic pain is always challenging. It is essential to recognize neuropathic pain, identify the underlying cause, assess the impact of pain on the quality of life of the patient and initiate appropriate treatment. This article limits itself to discuss about the Neuropathic pain pertaining to oro-facial structures. It includes Trigeminal Neural-gia, Post Herpetic Neuralgia (PHN), cancer neuropathic pain, HIV neuropathy.

## Conditions Causing Neuropathic Pain

Neuropathic pain is caused due to damage to the neural functions. Neuropathic pain is most often consequences of a disease, rather the disease itself. It could be due to traumatic nerve damage or compression, diabetes, cancer, chemotherapy, viral infection, alcohol, and surgical amputation<sup>[4]</sup> [Table 1] - conditions causing neuropathic pain]. Pain can be central or peripheral based on which it is categorized as central neuropathic pain or peripheral neuropathic pain.

## Pathophysiology

The peripheral and central mechanism together may contribute to the symptoms.<sup>[5-12]</sup> This can be given as follows [Figure 1]:

1. Nociceptors evoke the pathological activity.
2. Ectopic activity of damaged neuron and dorsal root ganglion cells.
3. Increased release of neurotransmitter due to increased sodium channel activity.
4. Increased afferent pathway activity causing central sensitization of dorsal horn neurons.
5. Increased central facilitation.

### Access this article online

Website: [www.japer.in](http://www.japer.in)

E-ISSN: 2249-3379

**How to cite this article:** Subha M, Arvind M. Therapeutics in neuropathic pain - An overview. J Adv Pharm Edu Res 2017;7(3):216-221.

**Source of Support:** Nil, **Conflict of Interest:** None declared.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

## Clinical Features

Neuropathic pain has a wide range of expression other than pain itself. It includes allodynia, anesthesia, hyperalgesia, hyperpathia, hypoesthesia, paraesthesia, and phantom pain. They are categorized as negative symptoms and positive symptoms. Negative symptoms include anesthesia and hypoesthesia which are due to impaired

**Table 1: Common causes of neuropathic pain**

Metabolic	Multiple sclerosis
Diabetes mellitus	Monoclonal gammopathies
Vitamin B deficiency	Guillain-Barre syndrome
Toxic	Genetic
Drugs - isoniazid, phenytoin, hydralazine, vincristin, vinblastine	Hereditary motor and sensory neuropathy
Metal poisoning - lead, mercury	Vascular
Trauma	Vasculitis
Phantom pain	Cerebrovascular disorder
Complex regional pain syndrome	Carcinomatous
Carpel tunnel syndrome	Paraneoplastic syndrome
Infection	Compression or infiltration of tumour
Herpes zoster	Neuralgia
HIV	Trigeminal
Epstein barr virus	Post herpetic
Immune	Hypoglossal

**Table 2: Steps in diagnosis of neuropathic pain**

Step 1	History	Suggestive of neural distribution (central and peripheral)	Possible
Step 2	Clinical examination and investigation	Negative/positive sensory signs and confirmatory tests	Probable
Step 3	History+clinical finding+confirmatory tests. All positive		Definitive

Adapted from Treede RD, Jensen TS, Cambell *et al.* Neuropathic pain redefining a grading system for clinical and research purpose. *Neurology* 2008;70:1630-5

**Table 3: Conditions and the drug of choice**

Disorder	Clinical features	Drug of choice
Trigeminal neuralgia	Paroxysmal attacks of electric shock-like pain along the course of trigeminal nerve lasting for few second to minutes. Pain is aggravated from trigger areas by certain activities such as shaving, washing face, and brushing <sup>[9]</sup>	First line: Carbamazepine, oxcarbazepine Second line: Lamotrigine, baclofen Third line: Gabapentin, pregabalin, amitriptyline, duloxetine or venlafaxine <sup>[16,17]</sup>
PHN	HZ is unilateral, does not cross the midline, and is localized to a single dermatome of a single sensory ganglion. In orofacial region, it affects the trigeminal nerve. Characterized by prodromal symptoms followed by distribution of rashes along the nerve course <sup>[18]</sup>	First line: Amitriptyline or nortriptyline, pregabalin, and gabapentin along with topical lidocaine (5% paste) Second line: Topical capsaicin (0.025%) Third line: Baclofen or tramadol, memantine, lorazepam <sup>[19,21]</sup>
Central pain	Constant, spontaneous, lancinating pain, may be associated with pruritis caused due to nerve injury <sup>[22]</sup>	First line: Amitriptyline and nortriptyline, pregabalin, or gabapentin Second and third line: Lamotrigine, tramadol, or opioids (morphine/fentanyl) <sup>[17,19]</sup>
HIV neuropathy	Distal sensory neuropathy due to demyelination of peripheral fibers results in severe neuropathic pain <sup>[23]</sup>	First line: Amitriptyline or nortriptyline and pregabalin or gabapentin along with serotonin reuptake drugs duloxetine or venlafaxine Second line: Tramadol or tramadol with paracetamol Third line: Lamotrigine or topical capsaicin <sup>[17,19,20]</sup>
Oncologic neuropathic pain	It occurs due to tumor invasion, infiltration, or abnormality in protein processing due to chemotherapy or radiation therapy <sup>[24]</sup>	First line: Tricyclic antidepressants and anticonvulsants Second line: Tramadol and opioids Third line: Selective serotonin reuptake inhibitors <sup>[17,20,21]</sup>

PHN: Post-herpetic neuralgia

afferent or efferent conduction. Positive symptoms include all other symptoms mentioned above which are due to increased or ectopic neuronal activity.

Neuropathic pain can also be classified based on their responds to stimuli as stimulus dependent and stimulus independent. Stimulus-evoked pain occurs due to slightest stimuli such as clothing or a non-painful touch. Stimulus-independent pain is spontaneous. It is continuous or intermittent, usually burning, shooting, or shock-like. It is mainly due to decreased inhibitory input from the brain and spinal cord. Although we classify them as stimulus dependent and independent, the symptoms occur as combinations which make it difficult to categorize under one particular type.<sup>[13,14]</sup>

## Assessment of Neuropathic Pain

### History

A detailed history helps us to understand the nature and characteristics of pain. History will indicate if the distribution and characteristics of pain categorize it as neuropathic pain criteria or it is due to some neurological lesion or condition.<sup>[15]</sup>

### Clinical Examination

In most case, neuropathic pain is a syndrome that is a constellation of signs and symptoms with numerous underlying etiologies, and hence, a complete neurological examination and sensory testing are essential to call it a neuropathic pain [Table 2]. Examining the somatosensory system reveals positive symptoms such as hyperalgesia and allodynia and negative symptoms such as paresthesia and loss of function. This enables us to understand the underlying disease or lesion.<sup>[15]</sup>

Table 4: Drugs and dosage for neuropathic pain

Drugs	Dosage	Duration	Adverse effects	Evidence
<b>Tricyclic anti-depressant<sup>[25-29]</sup></b>				
Amitriptyline	25–150 mg/day, titrated weekly by	6-8 weeks	Sedation, confusion, anxiety, anticholinergic effects such as dry mouth, increased intraocular pressure, constipation, urinary retention, orthostatic hypotension	Rowbatham <i>et al.</i> (2005) - A parallel group study Chandra <i>et al.</i> (2006) - RCT with GPT
Imipramine	10 mg/day from 25 mg/day			
Nortriptyline				
<b>Serotonin-norepinephrine reuptake inhibitors<sup>[30-32]</sup></b>				
Duloxetine	30–120 mg/day titrated weekly by 30 mg/day from 30 mg/day	4 weeks	Asthenia, fatigue, nausea, vomiting, dry mouth, sedation, drowsiness, tremors. Its use is limited in patients with renal, hepatic and cardiovascular dysfunction	Ruskin <i>et al.</i> (2005) Wernick <i>et al.</i> (2006) Parallel-group RCTs
Venlafaxine	37.5–225 mg/day titrated weekly by 37.5 mg/day from 37.5 mg/day	4-6 weeks		Kadiroglu <i>et al.</i> (2008) - RCT
<b>Anticonvulsant<sup>[33,21,27,23,34]</sup></b>				
Gabapentin	300–3600 mg/day titrated weekly by 300 mg from 300 mg/day	3-8 weeks	Fatigue, drowsiness, dizziness, hyponatremia. Special precautions with cardiac problems, hepatic and renal failure is necessary	Wiffen <i>et al.</i> (2006) - RCT with placebo
Pregabalin	150-600 mg/day titrate by 50 mg/day from 150 mg/day	4 weeks		Vanseventel <i>et al.</i> (2006), Sidal <i>et al.</i> (2006), Vranken <i>et al.</i> (2009) - RCT with placebo
Carbamazepine	100-1200 mg/day titrated by 100 mg/day from 100 mg/day	4 weeks		Cruccu <i>et al.</i> (2008) Gronseth <i>et al.</i> (2006) - SR with 12 RCTs
Oxcarbazepine	300-1800 mg/day	4 weeks		Grosskopf <i>et al.</i> (2006) Parallel-group study with Placebo
<b>Topical Anesthetic<sup>[35-37]</sup></b>				
Lidocaine	3 plasters /day	3 weeks		Frank <i>et al.</i> (2009)- Cross over study Silver <i>et al.</i> (2007)-parallel group study Ho <i>et al.</i> (2008) - Crossover study
<b>Opioids<sup>[38-40]</sup></b>				
Morphine	30-120mg / day titrated by increasing 5 mg every 3 days from 15 mg/day 12 h	4-6 weeks	Constipation, vomiting, nausea, dizziness, drowsiness, headache, dry mouth, Abuse, addiction, withdrawal syndrome and suicidal tendency are the risks.	Raja <i>et al.</i> (2002) - Crossover study Edward <i>et al.</i> (2006)- Crossover study
Fentanyl	25-100 micro g/h	4 weeks		Gimbel <i>et al.</i> (2003), Jensen <i>et al.</i> (2005), Hanna <i>et al.</i> (2008) - RCT with placebo
Oxycodone	20–60 mg/day	4 weeks		
<b>Others</b>				
Capsaicin <sup>[41-43]</sup>	0.025%	4 weeks	Skin rash, erythema, burning sensation	Backonja <i>et al.</i> (2008)-RCT
Cannadidiols <sup>[44]</sup>	1-2 sprays every 4 h maximum 4 sprays on day one and titrated gradually	4-6 weeks		Nurmiko <i>et al.</i> (2010) - RCT


## Screening and Assessment Tools

These tools are used to distinguish neuropathic pain and non-neuropathic pain.

The McGill pain questionnaire describes the quality and characteristic of pain. The descriptors fall into four major groups, sensory, affective, effective, and miscellaneous. It have 102 descriptive words under

these 4 categories along with these pain rating index is also recorded which is the sum of the rank value of the scoring given in the above 4 categories. It also includes present pain index based on a scale of 0–5. Although it gives a detailed description on the characteristics of pain, it is not widely used as it lacks specificity, it is time-consuming, and it has a language barrier.<sup>[45,46]</sup>

Leeds assessment of neuropathic symptoms and signs (LANSS) pain scale enables differentiating neuropathic pain from non-



**Figure 1:** Pathophysiological interaction

neuropathic Pain. It has five symptom item and two clinical examination item. The score lies between 0 and 24 if its below and if its above 12 it is considered as neuropathic pain. It was modified, and later, modified with five items related to the quality of pain as self-reported scale S-LANSS. This has high sensitivity and specificity and is commonly used in epidemiology studies in general population.<sup>[47,48]</sup>

The neuropathic pain questionnaire (NPQ) is another questionnaire with 12 items (10 sensory and 2 affective), and it helps describe pain but does not reveal the etiology. A modification of this NPQ short forms with 3 items with discriminative properties to differentiate between neuropathic pain and non-neuropathic pain.<sup>[48,49]</sup>

The douleur neuropathique 4 questions have 7 items related to symptoms and 3 related to clinical examination. The 7 symptoms can be used as self-reported questionnaire also. Each question is graded with 1 point if positive, and hence, the total score ranges between 0 and 10, if the score is more than 4, it is categorized as neuropathic pain.<sup>[50,51]</sup>

Pain detect questionnaire is again a self-reported questionnaire with 9 items. It pain has 5 sensory descriptors used in joint pain as it specifically has one item to whether pain is located in joints.<sup>[14,15]</sup>

Pain quality assessment scale is a self-reported tool. It has 20 descriptors each graded from 0 to 10, and the sum total tells the intensity of pain.<sup>[52]</sup>

In the neuropathic pain symptom inventory, it has 12 items, 10 symptom descriptors, and 2 items to evaluate spontaneous and paroxysmal spontaneous pain. Each parameter is graded from 0 to 10, and the sum total describes the intensity of pain.<sup>[53]</sup>

## Neurophysiology

Eliciting the neurophysiology in neuropathic pain would be of great value in diagnosing and managing the disease. Although nerve conduction studies helps in eliciting the intensity of pain its not widely accepted and practised. This includes microneurography, recording pain related reflex and functional neuroimaging.<sup>[15]</sup>

## Microneurography

Is a minimally invasive technique in which single axon recordings from peripheral nerve is done on subjects when they are awake. It provides valuable information on physiology and pathophysiology of all nerve fiber group.<sup>[54-57]</sup>

## Pain-related Reflexes

Pain related reflexes are diagnostically useful tool for facial pain. Early R1 blink reflex and early SP1 masseter inhibitory reflex effectively reveal symptomatic forms of Trigeminal Neuralgia. The early R1 blink reflex is positive in ophthalmic post-herpetic neuralgia (PHN) as well. Nociceptive blink reflex was delayed in patients with atypical odontalgia.<sup>[15]</sup>

## Functional Neuroimaging

Positron emission tomography and functional magnetic resonance imaging measure cerebral blood flow (rCBF) or metabolic activity of the brain. In unilateral spontaneous neuropathic pain, there is decreased resting rCBF in contralateral thalamus. Thalamic hypoperfusion may be a marker of neuropathic and restoration of thalamic blood flow for treatment monitoring. However, there is no sufficient data to declare it.<sup>[58,59]</sup>

## Skin Biopsy

A punch biopsy of skin in the painful areas allows immunostaining and visualization of the intradermal terminals of A delta and C to measure intraepidermal nerve fiber density (IENFD). In Post Herpetic Neuralgia IENFD of the affected site shows lower density than the contralateral mirror image skin. The allodynia is due to surviving irritable nociceptors. In complex regional pain syndrome, there are quantitative and qualitative changes in skin innervation.<sup>[60,61]</sup>

## Management of Neuropathic Disorder

Neuropathic pain cannot be considered as a disease but is an effect of underlying clinical conditions. An injury or damage in the nervous system causes neuropathic pain, and hence, a proper understanding of the underlying cause helps us to diagnose and manage the disease better [Table 4]. Frequent reassessment is also required to provide an effective therapy to the patient. The therapeutic guidelines provided in Tables 3 and 4 are based on a review of guidelines on the management of neuropathic pain.

## Conclusion

Neuropathic pain management is not only just management of the disease but also management of symptoms alone. The management of neuropathic pain starts from assessing the pain itself. To choose a suitable medicine for an individual patient, we should analyze the clinical condition, select management options wisely, determine the dosage required, check for any comorbidities condition, monitor the

outcome, reassess the condition, and do necessary modification in the drugs prescribed and the dosage if required.

## References

- Merskey H, Bogduk N. Classification of Chronic Pain. Seattle: IASP Press; 1994.
- Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. *Clin J Pain* 2007;23:143-9.
- Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: A systematic review and meta-analysis of health utilities. *Pain* 2010;149:338-44.
- Demarin V, Basic-Kes V, Zavoreo I, Bosnar-Puretic M, Rotim K, Lupret V, et al. Recommendations for neuropathic pain treatment. *Acta Clin Croat* 2008;47:181-91.
- Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H, Quality Standards Committee of the American Academy of Neurology. Practice parameter: Treatment of postherpetic neuralgia: An evidence based report of the quality standards subcommittee of the American academy of neurology. *Neurology* 2004;63:959-65.
- Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. *Eur J Neurol* 2006;13:1153-69.
- Brainin M, Barnes M, Baron JC. Guidelines standard subcommittee of EFNS scientific committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations. *Eur J Neurol* 2004;11:577-81.
- Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. *Pain* 2004;110:461-9.
- Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. *Pain* 2005;118:289-305.
- Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. *Diabetes Metab Res Rev* 2005;21:231-40.
- Hemipenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in PHN: A quantitative systematic review. *PLoS Med* 2005;2:628-44.
- Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* 2005;3:CD005454.
- Kumar A, Pottabathini R, Bhatnagar A, Garg S, Gupta V. Pharmacological management of neuropathic pain: Current trends and possible approaches. *Arch Neurosci* 2017;4:e28998.
- Baron R. Mechanisms of disease: Neuropathic pain-A clinical perspective. *Nat Clin Pract Neurol* 2006;2:95-106.
- Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, et al. EFNS guidelines on neuropathic pain assessment: Revised 2009. *Eur J Neurol* 2010;17:1010-8.
- Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. *Eur J Neurol* 2006;13:1153-69.
- Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010;17:1113-e88.
- Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and post herpetic neuralgia. *Mayo Clin Proc* 2009;84:274-80.
- Amorim D. Pharmacological treatment of neuropathic pain: Review of oral and topical therapy recommendations. *Int J Clin Neurosci Ment Health* 2015;2:4.
- Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidencebased recommendations. *Pain* 2007;132:237-51.
- Frizzo H, Hasse P, Veronese R. Trigeminal neuralgia: An analytic review of the literature. *Brazilian Journal of Oral and Maxillofacial Surgery* 2004;4:212-17.
- Canavero S, Bonicalzi V. Central pain syndrome: Elucidation of genesis and treatment. *Expert Rev Neurother* 2007;7:1485-97.
- Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease. *J Peripher Nerv Syst* 2001;6:21-7.
- Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain: The intersection of cancer pain and neuropathic pain. *Oncologist* 2010;15 Suppl 2:3-8.
- Ryder S, Stannard C. Treatment of chronic pain: Antidepressant, antiepileptic and antiarrhythmic drugs. *Br J Anaesth* 2005;5:18-21.
- Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. *Mayo Clin Proc* 2010;85 3 Suppl:S3-14.
- Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidencebased recommendations. *Pain* 2007;132:237-51.
- Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. *Pain* 2005;118:289-305.
- McDonald AA, Portenoy RK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. *J Support Oncol* 2006;4:43-52.
- Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010;17:1113-e88.
- Mateos RG. Manual Práctico del Dolor Neuropático. Washington, DC.; Elsevier España, S.L. Granada; 2010.
- Attal N, Bouhassira D. Central neuropathic pain. In: Pappagallo M, editor. *The Neurological Basis of Pain*. New York: McGraw-Hill; 2005. p. 301-19.
- Santos MM, Freire AR, Rossi AC, Prado FB, Caria PH, Botacin PR. Trigeminal neuralgia: Literature review. *J Morphol Sci* 2013;30:1-5.
- Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* 2005;3:CD005454.
- Ballantyne J, Cousins M, Giamberardino M, Jamison R, McGrath P, Rajagopal M, et al. *Pharmacological Management of Neuropathic Pain*. Vol. 18. Seattle: IASP; 2010.
- Directorate-General for Health and the Portuguese Association for the Study of Pain. National Plan to Fight Pain; 2001. Available from: [http://www.apeddor.org/images/documentos/controlo\\_da\\_dor/Programa\\_Controlo\\_da\\_Dor.pdf](http://www.apeddor.org/images/documentos/controlo_da_dor/Programa_Controlo_da_Dor.pdf). [Last updated on 2017 Mar 10].
- Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the Canadian pain society. *Pain Res Manag* 2007;12:13-21.
- Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: A literature review. *Eur J Pain* 2007;11:490-518.
- Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009;10:113-30.

40. Wells J. Neuropathic pain, classification and management for general practitioners 2007;3:3-5.
41. Dworkin R, O'Connor A, Backonja M, Farrar J, Finnerup N, Jensen T, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. *Int Assoc Soc Psychiatry* 2007;132:237-51.
42. Neuropathic Pain. The Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings. NICE; 2010. Available from: <https://www.nice.org.uk/guidance/cg173/resources/guidance-neuropathicpain-pharmacological-management-pdf>. [Last updated on 2017 Feb ].9
43. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin Type A induces direct analgesic effects in chronic neuropathic pain. *Ann Neurol* 2008;64:274-84
44. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain – Consensus statement and guidelines from the Canadian pain society. *Pain Res Manag* 2007;12:13-21.
45. Melzack R. The McGill Pain Questionnaire. New York: Pain Management and Assessment, Raven Press; 1983.
46. Melzack R. The McGill pain questionnaire: Major properties and scoring methods. *Pain* 1975;1:277-99.
47. Bennett M. The LANSS pain scale: The Leeds assessment of neuropathic symptoms and signs. *Pain* 2001;92:147-57.
48. Eckeli FD, Teixeira RA, Gouvea AL. Neuropathic pain evaluation tool. *Rev Dor Sao Paulo* 2016;17 Suppl 1:S20-2.
49. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. *Clin J Pain* 2003;19:306-14.
50. Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. *Pain* 2011;152:14-27.
51. Santos JG, Brito JO, de Andrade DC, Kaziyama VM, Ferreira KA, Souza I, et al. Translation to Portuguese and validation of the douleur neuropathique 4 questionnaire. *J Pain* 2010;11:484-90.
52. Jensen MP, Gammaitoni AR, Olaleye DO, Oleka N, Nalamachu SR, Galer BS. The pain quality assessment scale: Assessment of pain quality in carpal tunnel syndrome. *J Pain* 2006;7:823-32.
53. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the neuropathic pain symptom inventory. *Pain* 2004;108:248-57.
54. Bostock H, Campero M, Serra J, Ochoa JL. Temperature-dependent double spikes in C-nociceptors of neuropathic pain patients. *Brain* 2005;128:2154-63.
55. Ochoa JL, Campero M, Serra J, Bostock H. Hyperexcitable polymodal and insensitive nociceptors in painful human neuropathy. *Muscle Nerve* 2005;32:459-72.
56. Orstavik K, Jørum E. Microneurographic findings of relevance to pain in patients with erythromelalgia and patients with diabetic neuropathy. *Neurosci Lett* 2010;470:180-4.
57. Serra J, Campero M, Bostock H, Ochoa J. Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia. *J Neurophysiol* 2004;91:2770-81.
58. García-Larrea L, Maarrawi J, Peyron R, Costes N, Mertens P, Magnin M, et al. On the relation between sensory differentiation, pain and thalamic activity in Wallenberg's syndrome: A PET-scan study before and after motor cortex stimulation. *Eur J Pain* 2006;10:677-88.
59. García-Larrea L, Peyron R, Mertens P, Gregoire MC, Lavenne F, Le Bars D, et al. Electrical stimulation of motor cortex for pain control: A combined PETscan and electrophysiological study. *Pain* 1999;83:259-73.
60. Hsieh JC, Belfrage M, Stone-Elander S, Hansson P, Ingvar M. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. *Pain* 1995;63:225-36.
61. Iadarola MJ, Max MB, Berman KF, Byas-Smith MG, Coghill RC, Gracely RH, et al. Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. *Pain* 1995; 63:55-64